Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of LY01011 vs Xgeva in Healthy Adults
NCT04198636Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of LY01011 in skeletal-related events (SRE), Giant Cell Tumor of Bone (GCTB) and hypercalcemia of malignancy (HCM) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Maximum Observed Serum Concentration at 168 days and Area Under the Serum Concentration-Time Curve from Time Zero to Time t at 168 days. Status: unknown.
02
Drugs
LY01011
03
Conditions
skeletal-related events (SRE)Giant Cell Tumor of Bone (GCTB)hypercalcemia of malignancy (HCM)
Beyond the preview
Go deeper on NCT04198636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198636.